Nuclear Medicine Market Analysis
The nuclear medicine market is valued at USD 17.43 billion in 2025 and is forecast to climb to USD 30.91 billion by 2030, expanding at a 12.15% CAGR. Precision‐oncology protocols, rapid regulatory approvals for next-generation radiopharmaceuticals, and imaging innovations that capture disease at earlier stages are the principal growth catalysts. Government initiatives that favor domestic isotope production, stronger reimbursement for high-cost tracers, and AI-enabled workflow acceleration further reinforce demand. Therapeutic radioligands are gaining momentum as lutetium-177 moves beyond prostate cancer, while diagnostics still command three-quarters of revenue thanks to technetium-99m’s entrenched use in SPECT. North America retains leadership, yet Asia-Pacific is setting the growth pace on a double-digit trajectory as infrastructure investments and harmonized regulations close historical gaps. Supply-chain resilience now shapes competitive strategy, driving vertical integration and capacity expansions across the nuclear medicine market.
Key Report Takeaways
- By product type, diagnostics led with 75.15% revenue share in 2024, while therapeutics are advancing at a 19.78% CAGR to 2030.
- By radioisotope, technetium-99m held 42.68% of the nuclear medicine market share in 2024; lutetium-177 is projected to grow at a 15.37% CAGR through 2030.
- By application, cardiology accounted for 40.82% of the nuclear medicine market size in 2024, whereas oncology is expanding at a 13.89% CAGR through 2030.
- By end user, hospitals dominated with 54.26% share in 2024; specialized radiopharmacies are forecast to rise at a 13.43% CAGR to 2030.
- By geography, North America commanded 45.99% share in 2024, yet Asia-Pacific is the fastest‐growing region at a 12.77% CAGR to 2030.
Global Nuclear Medicine Market Trends and Insights
Drivers Impact Analysis
| Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Rising burden of targeted diseases | +2.8% | North America & Europe, global spill-over | Long term (≥ 4 years) |
| Adoption of targeted radiotherapy | +3.2% | Global, APAC uptake accelerating | Medium term (2-4 years) |
| Imaging‐technology advances | +2.1% | North America & EU core, APAC spill-over | Short term (≤ 2 years) |
| Personalized and precision medicine shift | +2.4% | Early adoption in developed markets | Long term (≥ 4 years) |
| Government and private investment focus | +1.7% | US, China, Europe | Medium term (2-4 years) |
| Theranostics plus supportive reimbursement | +2.9% | North America & EU, global rollout | Medium term (2-4 years) |
| Source: | |||
Rising Burden of Targeted Diseases
Escalating prevalence of cardiovascular, oncologic, and neurological disorders is pushing clinicians toward modalities that offer molecular precision unavailable in conventional imaging. Cardiology alone represents 40.82% of procedures in 2024, yet oncology shows the fastest expansion as radioligand therapy gains evidence across metastatic indications. Pediatric clearance of lutetium Lu 177 dotatate widened the eligible population for neuroendocrine tumors, underscoring nuclear medicine’s reach into rare-disease care.[1]Food and Drug Administration, “FDA approves lutetium Lu 177 dotatate for pediatric patients 12 years and older with GEP-NETs,” fda.gov Ultra-high resolution PET systems now visualize sub-2 mm lesions, improving early neurological diagnoses and reinforcing the nuclear medicine market’s role in complex-disease management.[2]
Growing Adoption of Targeted Radiotherapy
Radioligand therapies integrate diagnostic imaging and therapeutic dosing, reshaping cancer care pathways. The global theranostics field is projected to multiply fivefold by 2032 as alpha emitters such as actinium-225 demonstrate higher tumor-killing potency, prompting commercial production ramp-ups. Real-world data for 177Lu-PSMA-617 show 73.5% survival and clinically meaningful PSA responses, encouraging earlier-stage deployment and broadening indications.[2]Journal of Nuclear Medicine, “Performance Characteristics of the NeuroEXPLORER, a Next-Generation Human Brain PET/CT Imager,” snmjournals.org These outcomes reinforce confidence among oncologists and healthcare payers, propelling the nuclear medicine market.
Technological Advancement in Imaging Modalities
Next-generation hardware and AI software are increasing sensitivity while slimming radiation doses. Generative-AI reporting tools cut radiologist turnaround by up to 40%, easing workflow bottlenecks. Virtual CT algorithms halve exposure during PET/CT studies without compromising diagnostic value. Total-body PET systems multiply sensitivity, enabling fast, low-dose scans that expand patient eligibility across the nuclear medicine market.
Shift Toward Personalized and Precision Medicines
Image-based dosimetry and radiomics analytics allow therapies to be tailored to each patient. Machine-learning models now compute time-integrated activity from single-point scans with ≤27% deviation from multi-time-point standards. Copper-61 PSMA tracers featuring a 3.33-hour half-life support delayed imaging to detect micro-lesions, aiding precision oncology programs. These advances align with value-based care initiatives that prioritize outcome optimization.
Restraints Impact Analysis
| Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Complex multi-agency regulatory approval | -1.8% | EU, emerging economies, global | Long term (≥ 4 years) |
| Short half-life isotope supply-chain risk | -2.3% | Global, remote regions | Short term (≤ 2 years) |
| High cost of procedures and equipment | -1.5% | Emerging markets, cost-pressured regions | Medium term (2-4 years) |
| Scarcity of skilled radiopharmacists | -1.1% | APAC and developing economies | Long term (≥ 4 years) |
| Source: | |||
Complex Multi-Agency Regulatory Approval
Radiopharmaceuticals must comply with drug, radiation, and sometimes device regulations, stretching timelines and raising costs. Europe operates nine distinct frameworks for unlicensed preparations, fragmenting access and slowing innovation. Conversely, the FDA has trimmed reporting burdens for low-risk diagnostics, spotlighting how harmonization can improve market agility.
Short Half-Life Isotope Supply-Chain Risk
Unexpected reactor outages in 2024 cut molybdenum-99 availability by up to 100%, curtailing technetium-99m procedures and highlighting a chronic fragility in the nuclear medicine market. Cyclotron-based gallium-68 production offers an alternative, yet most regions lack the infrastructure to pivot rapidly.
Segment Analysis
By Product Type: Therapeutics Gain Ground Amid Diagnostic Dominance
Diagnostics generated 75.15% of revenue in 2024, supported by technetium-99m’s ubiquity and well-established SPECT infrastructure. Yet therapeutics are forecast to grow at 19.78% annually, illustrating a pivot toward disease-modifying treatments. The nuclear medicine market size for therapeutics is expected to more than triple between 2025 and 2030 as prostate, neuroendocrine, and potentially renal cancers adopt radioligand regimens. FDA clearance of flurpiridaz F-18 simultaneously extends PET into stress-testing protocols, broadening diagnostic reach.
Beta emitters such as lutetium-177 dominate therapy today, but alpha emitters are entering clinical practice as capacity builds. Eckert & Ziegler’s actinium-225 rollout and Curium’s expanded lutetium-177 line promise to ease supply bottlenecks. Diagnostics are modernizing as total-body PET and AI report-generation penetrate routine practice, preserving their central role within the nuclear medicine market.
By Radioisotope: Lutetium-177 Disrupts Technetium-99m Leadership
Technetium-99m retained 42.68% share in 2024, benefiting from decades of clinical evidence and global logistics built around its six-hour half-life. Nevertheless, lutetium-177 is advancing at a 15.37% CAGR, reflecting therapeutic momentum and emerging supply solutions such as ytterbium-176 quantum enrichment. The nuclear medicine market size for lutetium-177 therapies is set to expand as oncology indications multiply.
Fluorine-18 remains the workhorse PET isotope, leveraging cyclotron scalability and a near two-hour half-life that eases shipping. Novel isotopes like terbium-161 and lead-212 are progressing through trials, offering higher linear energy transfer or unique decay schemes that could further diversify the nuclear medicine market.
By Application: Oncology Closes the Gap With Cardiology
Cardiac imaging represented 40.82% of procedures in 2024, driven by SPECT perfusion studies and expanding PET adoption after flurpiridaz F-18 approval. Oncology, however, is forecast to grow 13.89% per year as radioligand therapy gains guideline endorsements. Nuclear medicine market share for oncology applications will rise steadily as survival benefits translate to earlier-stage use.
Neurology benefits from ultra-high resolution PET that detects amyloid and tau deposition in prodromal Alzheimer’s disease. Endocrinology continues to rely on iodine-131 for thyroid disorders, while orthopedics explores bone-seeking agents for pain palliation. These diverse clinical needs sustain a broad procedural mix, ensuring balanced growth across the nuclear medicine market.
By End User: Centralized Radiopharmacies Redefine Supply Chains
Hospitals commanded 54.26% share in 2024 because most imaging suites remain hospital based. Specialized radiopharmacies are set to grow 13.43% annually as central compounding improves isotope utilization and minimizes waste. Nuclear medicine market size for radiopharmacy services will benefit from just-in-time logistics and turnkey solutions.
Imaging centers capitalize on cost-efficient equipment leases and CMS reimbursement reforms to expand PET capacity. Research institutes continue to pilot novel tracers, with more than 390 nuclear medicine studies initiated in the UK alone over the last decade. Ambulatory centers are adopting instant dosimetry protocols that shorten patient visits, extending access to outpatient settings.
Geography Analysis
North America generated 45.99% of global revenue in 2024, supported by clear reimbursement, advanced infrastructure, and domestic manufacturing initiatives. CMS’s payment separation policy in 2025 removes a key utilization barrier, while Indiana’s emerging isotope hub houses new facilities from Cardinal Health, Eli Lilly, and Novartis, reinforcing supply security. First clinical doses of flurpiridaz F-18 administered in February 2025 mark a milestone that should broaden cardiac PET adoption across the nuclear medicine market.
Asia-Pacific is the fastest-growing region, expanding at 12.77% CAGR as China ramps domestic isotope programs and Japan deepens industry capacity through GE HealthCare’s full acquisition of Nihon Medi-Physics. India’s 300 plus centers of excellence and Australia’s lead in advanced therapies further propel regional demand. Harmonized regulations and infrastructure investments are steadily reducing historic access gaps and positioning Asia-Pacific as a pivotal growth engine for the nuclear medicine market.
Europe retains a strong R&D footprint, buoyed by projects like Orano Med’s lead-212 plant and Curium’s new lutetium-177 site. Although national regulatory heterogeneity slows market entry, EU-funded consortia such as Thera4Care aim to streamline theranostic adoption.[3]Curium Pharma, “Curium Announces the Official Opening of Its New Netherlands Facility for the Production of Lutetium-177,” curiumpharma.comA 250% rise in molecular radiotherapy sessions since 2007 highlights clinical momentum despite policy complexity. These advances sustain Europe’s relevance, albeit at a more measured growth pace compared with Asia-Pacific within the nuclear medicine market.
Competitive Landscape
The nuclear medicine market shows moderate consolidation. Eighty-six acquisitions since 2020 illustrate a scramble to secure isotope supply and therapeutic portfolios. Novartis internalized U.S. isotope capacity with a USD 200 million plant, while GE HealthCare deepened Asian reach through its Nihon Medi-Physics purchase. Curium cemented its leadership in lutetium-177 by acquiring Monrol, adding reactor and cyclotron capacity to satisfy cancer-therapy demand.
Smaller innovators contribute agility and niche expertise. ASP Isotopes applies quantum enrichment to ytterbium-176, alleviating lutetium-177 bottlenecks, while Telix combines AI imaging algorithms with proprietary tracers to offer an integrated care platform. Cardinal Health’s nationwide radiopharmacy network secures same-day PET deliveries, underscoring the advantage of vertically integrated distribution. Regulatory acumen becomes a differentiator as firms navigate diverging international frameworks that could otherwise delay product launches.
Emerging isotopes create white-space opportunities. Actinium-225 and terbium-161 promise superior tumor efficacy but require novel production routes. Partnerships between Telix and Eckert & Ziegler on actinium-225 technology exemplify collaboration models aimed at overcoming supply limits. Sustained investment in capacity, technology, and regulatory alignment will shape competitive positions as the nuclear medicine market evolves over the next decade.
Recent Industry Developments
- March 2025: GE HealthCare completed the acquisition of Nihon Medi-Physics, gaining full control of Japan’s leading radiopharmaceutical supplier.
- March 2025: Curium finalized the acquisition of Monrol, boosting lutetium-177 output and expanding PET capabilities.
- March 2025: FDA approved Telix’s Gozellix prostate-cancer imaging agent, widening PSMA-targeted diagnostic options.
- February 2025: FDA accepted Telix’s BLA for TLX250-CDx kidney-cancer imaging with priority review.